SailPoint and Rackspace Collaborate to Deliver Cloud-Hosted Identity Governance
SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, announced a strategic agreement with Rackspace®, which provides multi-cloud services across applications, data, security and infrastructure. The agreement enables organizations to host their identity governance programs in the cloud while leveraging Rackspace’s cloud expertise in helping guide businesses through each phase of their cloud transformation journey. Building on SailPoint’s flexible delivery strategy announced earlier this year, Rackspace joins SailPoint’s cloud hosting partner program to offer a managed service provider (MSP) solution for enterprises that want to deploy SailPoint’s IdentityIQ or SecurityIQ in Amazon AWS and Microsoft Azure environments.
“Organizations today have complex, and increasingly hybrid, IT environments – no two organizations are alike. Many are leaning toward the cloud for the flexibility, scalability and cost savings benefits, with some opting for cloud-hosted managed services so they don’t need to maintain that expertise in-house,” said Harry Gould, vice president of worldwide alliances and channels for SailPoint. “By partnering with Rackspace, we’re giving our joint customers the chance to reap the benefits of best-in-breed identity governance deployed to the cloud-hosted environment they prefer. This is another step forward in our commitment to enabling customers to deploy identity ‘their way,’ no matter their infrastructure or identity needs.”
“There are many enterprises today that, understandably, lack the technical expertise and capacity to navigate the complexity of the cloud ecosystem, successfully migrate workloads to the cloud and operate cloud environments at scale,” said Prashanth Chandrasekar, senior vice president and general manager of managed public clouds at Rackspace. “The combined talent, skillset and domain expertise of SailPoint and Rackspace can help more companies get their identity governance programs off the ground by lifting the burden of migrating, managing and operating cloud workloads all on their own.”
Rackspace is modernizing IT in today’s multi-cloud world. By delivering IT as a service, it helps customers of all industries, sizes and locations, across private and public sectors, realize the power of digital transformation without the complexity and expense of managing it on their own. Its comprehensive portfolio of managed services across applications, data, security and infrastructure on the world’s leading public and private cloud platforms enables it to provide unbiased expertise.
This partnership underscores SailPoint’s commitment to bringing identity governance to all enterprises, regardless of their delivery option preference and their skills and resources. Global enterprises can choose to deploy SailPoint’s market-leading identity governance solutions via the following comprehensive options: cloud-hosting managed service, public cloud, data center or SaaS.
SailPoint: The Power of Identity™
SailPoint, the leader in enterprise identity governance, brings the Power of Identity to customers around the world. SailPoint’s open identity platform gives organizations the power to enter new markets, scale their workforces, embrace new technologies, innovate faster and compete on a global basis. As both an industry pioneer and market leader in identity governance, SailPoint delivers security, operational efficiency and compliance to enterprises with complex IT environments. SailPoint’s customers are among the world’s largest companies in a wide range of industries, including: 7 of the top 15 banks, 4 of the top 6 healthcare insurance and managed care providers, 9 of the top 15 property and casualty insurance providers, 5 of the top 15 pharmaceutical companies, and 11 of the largest 15 federal agencies.
SailPoint, the SailPoint logo, IdentityIQ, IdentityNow, IdentityAI, SecurityIQ and all techniques are trademarks or registered trademarks of SailPoint Technologies Holdings, Inc. in the U.S. and/or other countries. All other products or services are trademarks of their respective companies.
SailPoint Technologies Holdings, Inc.
Jessica Sutera, 978-278-5411
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 10:18:00 CEST | Pressemelding
The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 10:00:00 CEST | Pressemelding
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc
Enterprise Integration Middleware Leader, Fiorano Software, Announces Release of Fiorano Platform 12.024.4.2019 09:00:00 CEST | Pressemelding
Fiorano Software, a leader in Integration Middleware, API Management and peer-to-peer distributed systems, announced today the release of version 12.0 of the Fiorano ESB and API Management platform. The latest release with new adapters and tools includes enhanced and optimised features to improve performance of its servers delivering a more productive SOA and API Management deployment with a significant incremental return on investment. The platform offers a unified profile to run all Fiorano Servers in a single process and ships with several new adapters including a Kafka Connector, DynamoDB, AS4Connector, SMPPSend and WebSockets. Users can now import Event Processes directly from the Dashboard and optimize CRC processes by fetching components from local repositories. The new platform provides a new HTML5 dashboard, monetisation and security policies like JWT/JWS for API Management while supporting Open API specifications, OpenId Connect and time-based accessing and quota policies alo
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™24.4.2019 08:30:00 CEST | Pressemelding
Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019. SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization. It is the intention of the Smart Pharma group to continue to incorporate Aenco’s blockchain technology into its pharmaceutical development and commercialization processes. Relying on intellectual property derived from the Smart-ACT™ platform, Smart Pharma’s in-house new and repurposed
Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases24.4.2019 08:30:00 CEST | Pressemelding
Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005095/en/ (Photo: Business Wire) Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACTTM platform will initially focus on the screening drug molecules for orphan diseases or unmet medical needs. To date, SmartP has, under the recently established
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 201924.4.2019 08:15:00 CEST | Pressemelding
Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-negotiated transaction, repurchased all outstanding US$13,500,000 in aggregate principal amount of the 8.00 per cent. convertible bonds due 2019 (“Convertible Bonds”) from Peace Range Limited, a wholly owned subsidiary of Adamas Ping An Opportunities Fund LP, together with certain subscription right to subscribe up to the principal amount of the Bond at a US$12.17 (subject to adjustment) on or before December 17, 2019 (“Subscription Right”). The total consideration of the repurchase of the Convertible Bonds and the Subscription Right was US$13.6 million in cash, excluding accrued interest. The repurchase of the Convertible Bonds and Subscription Right was executed by Aptorum Investment Holding Limited, a wholly owned subsidiary